Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting Abstracts, 8–10 August 2012, Sofitel Brisbane, Queensland, Australia
Article first published online: 31 JUL 2012
© 2012 Blackwell Publishing Asia Pty Ltd
Asia-Pacific Journal of Clinical Oncology
Special Issue: Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting Abstracts, 8–10 August 2012, Sofitel Brisbane, Queensland, Australia
Volume 8, Issue Supplement S2, pages 12–14, August 2012
How to Cite
(2012), International Speakers. Asia-Pacific Journal of Clinical Oncology, 8: 12–14. doi: 10.1111/j.1743-7563.2012.01583_9.x
- Issue published online: 31 JUL 2012
- Article first published online: 31 JUL 2012
Professor Susan Chang is the Director of the Neuro-Oncology Division at the University of Californiaat San Francisco (UCSF), and she specialises in the treatment of adults with brain tumours. Professor Chang received a medical degree from the University of British Columbia and completed a residency in internal medicine at Toronto General Hospital in Canada. She completed a fellowship in medical oncology at Princess Margaret Hospital in Toronto as well as a fellowship in neuro-oncology at the UCSF, where she later joined the faculty. Professor Chang performs clinical trials about brain tumour therapy protocols and experimental therapeutic regimens for adult patients. In addition to research into developing novel and effective therapeutic strategies for the treatment of patients with primary brain tumours, her research includes the evaluation of novel imaging techniques that may influence treatment selection for patients. She has received NIH grant support to evaluate the role of magnetic resonance spectroscopy in diagnosing tumours and evaluating therapeutic interventions.
Professor Heinz-Josef Lenz is Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the Norris Comprehensive Cancer Center at the University of California at San Francisco (UCSF); overseeing research activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women's Cancers, Leukemia and Lymphoma Programs. He is also Professor of Medicine and Preventive Medicine, Head of Gastrointestinal Oncology, Division of Medical Oncology and, Co-Director of the Colorectal Center, Keck School of Medicine at USC. Professor Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, completing a residency in haematology and oncology at the University Hospital Tübingen in Germany, and clerkships in oncology at George Washington University in Washington, DC, and haematology at Beth Israel Hospital, Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in biochemistry and molecular biology at USC. Professor Lenz's research focuses on the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research (ACCR) and the National Society of Genetic Counsellors. He also serves on the National Advisory Boards of a number of professional organisations and has authored numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Co-Chair of the Gastrointestinal Committee and Correlative Science Committee for the National Cancer Institute's (NCI) SWOG. He is a member of the NCI Task Force for Gastroesophageal Cancer, Steering Committee and Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the American Society for Clinical Oncology (ASCO) Young Investigator Award and the ASCO Career Development Award.
Professor Lillian L. Siu is a senior staff medical oncologist and Director of the Phase I Program and Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Hospital and a Professor at the University of Toronto. She holds a Tier I Cancer Care Ontario Chair in Experimental Therapeutics and serves on the Board of Directors for American Society for Clinical Oncology (ASCO) from 2012–2016. Her major research focus is in the area of new anti-cancer drug development, particularly with respect to phase I trials and head and neck malignancies. Professor Siu is the Principal Investigator of many phase I, II and III trials supported by the National cancer Institute (NCI, United States of America), National Cancer Institute of Canada and the pharmaceutical industry. She is the Principal Investigator of a phase I cooperative agreement U01 award (2008–2013) NCI which aims to expedite the access and evaluation of novel anti-cancer agents for patients, optimise clinical trials design of new agents, and characterise the effects of new agents on their targets with clinically relevant endpoints, through the integration of suitable biochemical, pathological, immunological, molecular, and/or imaging methods. In addition to her active research in early phase clinical trials, Professor Siu has also been leading genomics initiatives in the area of personalised cancer medicine at the Princess Margaret Hospital. Professor Siu has extensive experience in the training and mentorship of young oncologists serving on the Program Committees for both the Federation of European Cancer Societies, ASCO, American Association for Cancer Research (AACR) workshop in Flims, Switzerland and the AACR and ASCO workshop in Vail, Colorado for the past few years, and is one of the course directors for the Flims Workshop in 2009–2011. As the co-director of the Princess Margaret Hospital Drug Development fellowship program she oversees training to ensure that young oncologists are exposed to a wide spectrum of research, educational and practical opportunities. Over the past decade, the fellowship program has consistently attracted trainees from cancer centres throughout the world. Professor Siu was the recipient of the 2010 NCI Michaele C. Christian Award in Oncology Drug Development and was the Neuroendocrine Tumor Task Force Chair in the North American Gastrointestinal Intergroup Scientific Steering Committee from 2007–2009. She was the Chairperson of the ASCO Grants Selection Committee in 2009–2010 and the AACR Education Committee for the 2012 Annual Meeting. Professor Siu has published over 130 peer-reviewed manuscripts, she is currently an editor for European Journal of Cancer, Journal of Clinical Oncology and Cancer Discovery.
Professor Alberto Sobrero has been the Head of the Medical Oncology Unit at Ospedale San Martino in Genova, Italy, since 2001. Before this, he was Associate Professor in Medical Oncology at the University of Florence and Udine. After receiving his medical degree from the University of Genova in 1978, Professor Sobrero took up the position of postdoctoral Associate in Medical Oncology at Yale University, Connecticut, United States of America. In 1983, he became Associate Research Scientist in Medical Oncology at Yale. Before returning to Genova in 1985, he completed a residency in Internal Medicine at the Yale Affiliated Norwalk Hospital. In addition to being a member of several Italian scientific societies, Professor Sobrero is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO). From 2002 to 2006, Professor Sobrero has been the Chairman of the Protocol Review Committee of the European Organisation for Research and Treatment of Cancer and has been part of the faculty of the ASCO – Federation of European Cancer Societies Clinical Research courses at Flims for 7 years. He has served on the editorial board of the Journal of Clinical Oncology 2004–2006, has been part of the Scientific Committee of ASCO (2007–2008) and of the Educational Committee of ESMO (2008–2012). His main research interests include gastrointestinal cancer treatment and design and interpretation of clinical trials in oncology.
Professor Ian F. Tannock is the Daniel E. Bergsagel Professor of Medical Oncology at the Princess Margaret Hospital and the University of Toronto, Canada. Professor Tannock obtained his PhD in London, England for studies of cell population kinetics. After postdoctoral studies at MD Anderson Hospital, he studied medicine at University of Pennsylvania, United States of America. He completed training as a medical oncologist at Princess Margaret Hospital in 1978, and apart from a sabbatical year in France has remained there as a clinician and scientist. Professor Tannock's clinical research has investigated methodological issues related to cancer clinical trials, with emphasis on endpoints of clinical benefit. He chaired sequential randomised clinical trials for men with metastatic prostate cancer that led to licensing of previous (mitoxantrone) and current (docetaxel) chemotherapy. His laboratory-based research evaluates the effects of the solid tumour microenvironment on outcome of cancer therapy. His laboratory is particularly interested in limited drug distribution within solid tumours as an important and neglected cause of clinical drug resistance and in strategies to complement or modify that limited distribution. Professor Tannock was a member of the American Society of Clinical Oncology Board of Directors. He has received the MD Anderson Outstanding Alumnus award and the Warwick Prize from the National Cancer Institute of Canada, for research that impacted on cancer control. He received an honorary Doctor of Science degree from London University, United Kingdom in 2009. He chairs the scientific audit committee of the European Organisation for Research and Treatment of Cancer.
Professor Michael A. Vogelbaum is Associate Director, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, United States of America. A graduate of the University of Virginia School of Medicine, Charlottesville, he received his specialty training in neurosurgery at the Barnes-Jewish Hospital, St. Louis and is board-certified in neurological surgery. Specialising in the diagnosis and treatment of benign and malignant tumours of the brain and spinal cord, Professor Vogelbaum is also interested in stereotactic (image-guided) surgery, Gamma Knife therapy and the molecular biology of brain tumours. He has joint appointments with the Cleveland Clinic Gamma Knife Center and the Lerner Research Institute's Department of Cancer Biology. He is Associate Director of the Brain Tumor and NeuroOncology Center and Director of the Center for Translational Therapeutics at Cleveland Clinic. In addition to his clinical duties, Professor Vogelbaum is an active research scientist. He was the recipient of the American Association of Neurological Surgeons Young Clinician Investigator Award, and receives support and funding from the American Cancer Society, the National Institute of Health and the Wolf Family Foundation. He and the members of his research laboratory are presently investigating new approaches for the treatment of primary and metastatic brain tumours. Professor Vogelbaum is Co-Chair of the Brain Tumor Committee and Chair of the Neurosurgery subcommittee for the Radiation Therapy Oncology Group. He has submitted patents for new devices for drug delivery to the brain and is currently involved in the clinical development of the first of these devices. He is currently the Vice President of the Society for NeuroOncology.